Biologics and monoclonal antibodies (MAbs) will become a bigger presence within the asthma therapeutics market, according to a new report from business intelligence firm GBI Research.
The report notes that small molecules currently account for 98% of available products in this therapeutic space, but highlights that the asthma pipeline consists of 12% MAbs and 17% non-MAb biologics.
One of the few currently-marketed MAb asthma therapeutics is Xolair (omalizumab) from Roche (ROG: SIX) subsidiary Genentech, which reached blockbuster status in 2014. It is approved for adults and adolescents aged 12 and over, with moderate-to-severe allergic asthma and symptoms not adequately controlled with inhaled corticosteroids.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze